- Leukemia (AML): Bristol-Myers Squibb Onureg was approved by EU
- Diet can change intestinal and breast flora and affects breast cancer risk
- WHO: Delta variant will become the world main popular variant virus strain
- Clinical application of interleukin in tumor immunotherapy
- Red meats: DNA damage and colorectal cancer-related gene mutations
- Why reversing intravenous thrombolysis after DOAC is not recommended?
First oral treatment for hereditary angioedema (HAE) was approved in EU!
First oral treatment for hereditary angioedema (HAE) was approved in EU! The first oral treatment for hereditary angioedema (HAE)! Plasma kallikrein inhibitor Orladeyo (berotralstat) was approved in EU!
BioCryst Pharmaceuticals recently announced that the European Commission (EC) has approved Orladeyo (berotralstat) capsules, an oral, once-daily drug for children and adult patients aged 12 years and older to prevent hereditary Onset of angioedema (HAE). In December 2020 and January 2021, Orladeyo was also approved for the same indications in the United States and Japan.
It is worth mentioning that Orladeyo is the first targeted oral therapy approved for the prevention of HAE attacks. The approval of the drug on the market has brought significant progress in the treatment of HAE patients who have been waiting for oral preventive treatment options, and will help reduce the treatment burden of patients.
The active pharmaceutical ingredient of Orladeyo is berotralstat, which is a new, oral, once-a-day, potent and selective inhibitor of human plasma kallikrein, which works by reducing the activity of plasma kallikrein. The drug was developed for HAE patients to prevent and treat the onset of angioedema. Currently, BioCryst is developing two formulations of berotralstat, capsules are developed to prevent HAE attacks, and oral liquid formulations are used to treat acute HAE attacks.
The chemical structure of berotralstat (picture source: probechem.cn)
Jon Stonehouse, President and CEO of BioCryst, said: “Currently, most European HAE patients use on-demand therapy or androgens to treat the disease. We believe that the oral, once-daily approval of Orladeyo will help Patients provide an exciting new opportunity to reduce their treatment burden by using Orladeyo for preventive treatment.”
Henrik Balle-Boysen, Executive Vice President and Chief Operating Officer of HAE International, a global network of non-profit patient associations dedicated to improving the lives of HAE patients, said: “Orladeyo provides the first oral non-steroidal drugs for HAE patients and their doctors in Europe. Prevent HAE attacks. This is an extremely important and most popular advancement in providing more available treatment options.”
berotralstat mechanism of action
In the pivotal Phase 3 APeX-2 trial, Orladeyo significantly reduced HAE episodes at the 24th week of treatment, and this reduction lasted until the 48th week. Among HAE patients who completed 48 weeks of treatment (150 mg), the HAE attack rate was an average of 2.9 attacks per month at the baseline examination, and decreased to an average of 1.0 attacks per month after 48 weeks of treatment. In the long-term open-label APeX-S trial, HAE patients who completed 48 weeks of treatment (150 mg) had an average of 0.8 seizures per month.
In 2 trials, Orladeyo was safe and well tolerated. Compared with the placebo group, the most commonly reported adverse reactions in patients taking Orladeyo were gastrointestinal reactions. These reactions usually occur early after the start of Orladeyo treatment, become less frequent over time, and usually disappear on their own.
Existing HAE preventive therapies have a significant treatment burden. In addition to reducing the rate of HAE attacks, data from the APeX-2 trial showed that in patients who took Orladeyo (150 mg) orally once a day, the quality of life and overall patient satisfaction were significantly improved, and the monthly standard care on-demand medication was significantly improved cut back.
Marc Riedl, an investigator of the APeX-2 trial and professor of medicine and clinical director of the Center for Hereditary Angioedema at the University of California, San Diego, said: “Patients and doctors agree that HAE treatment will increase the burden of life for patients. As a once-a-day oral With treatment options, Orladeyo can significantly reduce seizures and reduce the burden associated with injections and infusions.”
(source:internet, reference only)